Therapeutics and Clinical Risk Management (2020-06-01)

Derivation and Validation of a Risk Prediction Model for Vancomycin-Associated Acute Kidney Injury in Chinese Population

  • Xu N,
  • Zhang Q,
  • Wu G,
  • Lv D,
  • Zheng Y

Journal volume & issue
Vol. Volume 16
pp. 539 – 550


Read online

Nana Xu,1,2 Qiao Zhang,1,2 Guolan Wu,1,2 Duo Lv,1,2 Yunliang Zheng1,2 1Research Center of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 2Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of ChinaCorrespondence: Yunliang ZhengThe First Affiliated Hospital, Zhejiang University School of Medicine, 79# Qingchun Road, Hangzhou, Zhejiang 310003, People’s Republic of ChinaEmail [email protected]: Vancomycin is the standard therapy for methicillin-resistant Staphylococcus aureus (MRSA) infection; however, nephrotoxicity happened with a high incidence of 15%∼ 40%. Weighting the risk before receiving vancomycin treatment facilitates timely prevention of nephrotoxicity, but no standardized strategy exists for this purpose.Methods: A retrospective cohort study was performed. A total of 524 hospitalized patients treated with vancomycin were included in this study. They were divided into derivation cohort (n=341) and externally validation cohort (n=183) according to their admission time. Using univariate and multivariable logistic regression, we identified potential predictors of vancomycin-associated acute kidney injury (AKI) and developed a risk score by plotting nomogram. The predictive performance of this novel risk score was assessed and validated by discrimination and calibration. Besides, the risk score was also compared with existing prediction models according to integrated discrimination index (IDI) and net reclassification index (NRI).Results: The incidence of AKI was 16.1% (55/341) in the derivation cohort and 16.4% (30/183) in the validation cohort. Three factors (vancomycin serum trough concentration, piperacillin/tazobactam and furosemide) were determined as predictors for vancomycin-associated AKI. The established three-item risk score showed a comparable discrimination in both derivation cohort (AUC=0.793, 95% CI: 0.732– 0.855) and validation cohort (AUC=0.788, 95% CI: 0.698– 0.877). The risk score also demonstrated a good calibration in the derivation cohort (χ2=6.079, P=0.638> 0.05) and validation cohort (χ2=5.665, P=0.686> 0.05). Compared with prediction by Cmin alone, this risk score significantly improved reclassification accuracy (IDI=0.050, 95% CI: 0.024– 0.076, P< 0.001, NRI=0.166, 95% CI: 0.044– 0.289, P=0.007).Conclusion: The established model in this study is a simplified three-item risk score, which provides a robust tool for the prediction of AKI after receiving vancomycin treatment.Keywords: vancomycin, acute kidney injury, prediction model